Latest

Material developments from NSE, interpreted by CapitSignal.

Today

Monday, 21 September 2026

Today Yesterday 7 days

30Material events 3Earnings 6Business 9Capital 4M&A 1Governance 3Regulatory 4Distress

Augmont Enterprises LimitedAUGMONT20:31Low

Augmont board approves June-quarter unaudited standalone and consolidated results

Earningsresults

As filed

Augmont Enterprises Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

Why it matters

CapitSignal interpretation

The filing confirms the release and board approval of quarterly financial results, but the provided text does not include the underlying financial performance figures.

What happened

Fact

Augmont Enterprises’ board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The filing includes a limited review report for the consolidated results and identifies six entities in the group, including the parent company.

Full analysis Company memory

Lumino Industries LimitedLUMINO20:10Low

Lumino Industries approves unaudited June 2026 standalone and consolidated results

Earningsresults

As filed

Lumino Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

Why it matters

CapitSignal interpretation

The filing confirms the board’s approval and auditor review of the quarter’s results, but the financial figures themselves are not included in the provided text.

What happened

Fact

Lumino Industries’ board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review reports. The standalone review report stated that nothing had come to the auditors’ attention indicating a material misstatement or non-compliance with disclosure requirements.

Quarter ended June 30, 2026Reporting period
Period covered by the unaudited financial results
2LLPs included in standalone statement
Lumino Jupiter Solar LLP and Luminaard LLP

Full analysis Company memory

Symbiotec Pharmalab LimitedSYMBIOTEC20:00MixedNotable

Symbiotec’s Q1 consolidated PAT falls 53% as new businesses add costs

Earningsresults

As filed

Symbiotec Pharmalab Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Investor Release of Financial Results for the 1st Quarter ended June 30, 2026".

Why it matters

CapitSignal interpretation

The expanding new businesses are currently reducing consolidated profitability, despite 6% year-on-year API sales growth. Their planned revenue commencement over the next 6–12 months is important for validating returns on the company’s large capex programme.

What happened

Fact

Symbiotec reported Q1FY27 consolidated revenue of Rs. 218.2 crore, up from Rs. 203.2 crore in Q1FY26, while consolidated EBIDTA declined to Rs. 45.2 crore from Rs. 58.0 crore and PAT fell to Rs. 14.1 crore from Rs. 29.9 crore. The company attributed the drag to Rs. 23 crore of operating expenses and Rs. 12 crore of depreciation from new businesses that are not yet generating revenue; it expects revenue from various new businesses to begin in the next 6–12 months.

Rs. 218.2 croreConsolidated revenue
Q1FY27 consolidated revenue
Rs. 45.2 croreConsolidated EBIDTA
Q1FY27 consolidated EBIDTA
Rs. 14.1 croreConsolidated PAT
Q1FY27 consolidated profit after tax
Rs. 23 croreNew-business operating expenses
Q1FY27 expenses from new businesses not yet generating revenue
Rs. 12 croreNew-business depreciation
Q1FY27 depreciation from new businesses not yet generating revenue
approximately Rs. 1,666 croreEstimated gross capex
Estimated total gross capex by end-FY27
approximately Rs. 326 croreNet debt
Net debt as on September 20, after IPO proceeds

Watch next

Fact

Revenue commencement from new businesses over the next 6–12 months
Signing of the US distribution agreement for two DCV products and the second ANDA filing in early Q4FY27
Regulatory approval filing for insulin drug substance in Q4FY27

Full analysis Company memory